Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seven brokerages that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $4.00.
Several brokerages have commented on TNYA. Weiss Ratings downgraded Tenaya Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, November 10th. Wall Street Zen raised shares of Tenaya Therapeutics from a "strong sell" rating to a "sell" rating in a report on Sunday, September 6th.
Get Our Latest Report on Tenaya Therapeutics
Tenaya Therapeutics Price Performance
Shares of NASDAQ TNYA opened at $0.31 on Thursday. The business has a 50-day moving average of $0.49 and a 200-day moving average of $0.69. The company has a market capitalization of $69.95 million, a price-to-earnings ratio of -0.63 and a beta of 2.88. Tenaya Therapeutics has a 1-year low of $0.30 and a 1-year high of $1.46.
Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.02. The firm had revenue of $1.70 million during the quarter, compared to the consensus estimate of $0.80 million. Research analysts expect that Tenaya Therapeutics will post -0.36 EPS for the current fiscal year.
Institutional Investors Weigh In On Tenaya Therapeutics
Large investors have recently added to or reduced their stakes in the stock. Mirador Capital Partners LP boosted its position in shares of Tenaya Therapeutics by 2.0% during the second quarter. Mirador Capital Partners LP now owns 905,097 shares of the company's stock valued at $669,000 after buying an additional 18,180 shares during the period. Spark Investment Management LLC acquired a new position in shares of Tenaya Therapeutics in the second quarter worth about $26,000. R Squared Ltd grew its holdings in Tenaya Therapeutics by 136.0% in the third quarter. R Squared Ltd now owns 74,350 shares of the company's stock valued at $45,000 after purchasing an additional 42,847 shares during the period. Callan Family Office LLC purchased a new stake in Tenaya Therapeutics in the 2nd quarter worth $37,000. Finally, Raiffeisen Bank International AG raised its position in shares of Tenaya Therapeutics by 20.0% during the 2nd quarter. Raiffeisen Bank International AG now owns 1,200,000 shares of the company's stock worth $882,000 after purchasing an additional 200,000 shares during the last quarter. 90.54% of the stock is owned by institutional investors.
About Tenaya Therapeutics
(
Get Free Report)
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for heart disease. Based in South San Francisco, California, the company uses genetic medicine and other therapeutic approaches to target the underlying causes of cardiac conditions. Its investigational programs include TN-201, a gene therapy candidate for MYBPC3-associated hypertrophic cardiomyopathy, and TN-401, a gene therapy candidate for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tenaya Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tenaya Therapeutics wasn't on the list.
While Tenaya Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.